Featured Press Releases

EydisBio receives FDA Orphan Drug Designation for its TAK1 inhibitor to treat systemic sclerosis.

EydisBio receives FDA Orphan Drug Designation for its TAK1 inhibitor to treat systemic sclerosis.

Solu Therapeutics appoints Sergio Santillana, MD, as Chief Medical Officer to strengthen its leadership team.

Solu Therapeutics appoints Sergio Santillana, MD, as Chief Medical Officer to strengthen its leadership team.

  • 11 Sep 2024

Solu Therapeutics, a biotechnology company pioneering novel therapies to eliminate disease-driving cells in...

Find Therapeutics announces FDA clearance of its IND application for a Phase 1 study of FTX-101 to treat chronic optic neuropathy

Find Therapeutics announces FDA clearance of its IND application for a Phase 1 study of FTX-101 to treat chronic optic neuropathy

Hyundai Bioscience Develops Multi-Treatment for Mosquito-Borne Viral Infections, Including Dengue Feve

Hyundai Bioscience Develops Multi-Treatment for Mosquito-Borne Viral Infections, Including Dengue Feve

FDA Approves Arrowhead Pharmaceuticals’ REDEMPLO® (plozasiran) for Reducing Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS).

FDA Approves Arrowhead Pharmaceuticals’ REDEMPLO® (plozasiran) for Reducing Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS).

Avenacy announces launch of Eptifibatide for Injection in the U.S.

Avenacy announces launch of Eptifibatide for Injection in the U.S.

Leading Dermatologist Dr. Dendy Engelman Joins ELASTEN® to Advance the Future of Science-Backed Skin Health from Within

Leading Dermatologist Dr. Dendy Engelman Joins ELASTEN® to Advance the Future of Science-Backed Skin Health from Within

  • QUIRIS Healthcare
  • 11 Jun 2026
Breast Milk–Inspired Synbiotic for Infant Gut Health Developed Through Partnership Between NurtureBio and Lallemand

Breast Milk–Inspired Synbiotic for Infant Gut Health Developed Through Partnership Between NurtureBio and Lallemand

  • NurtureBio
  • 11 Jun 2026
SEREMI de Salud Grants Registration to Chile

SEREMI de Salud Grants Registration to Chile's First Finished Product Featuring Setria® Glutathione

  • Kyowa Hakko U.S.A
  • 11 Jun 2026
Roquette Highlights Scalable Innovations in Drug Delivery

Roquette Highlights Scalable Innovations in Drug Delivery

  • Roquette
  • 11 Jun 2026
X-Therma Launched XT-NoVo® and TimeSeal® Platform to Advance On-Demand Regenerative Medicine Beyond Cold Chain Constraints

X-Therma Launched XT-NoVo® and TimeSeal® Platform to Advance On-Demand Regenerative Medicine Beyond Cold Chain Constraints

  • X-Therma Inc.
  • 11 Jun 2026
IMAAVY® (nipocalimab-aahu) demonstrated rapid onset and durable hemoglobin response in a pivotal Phase 2/3 study of warm autoimmune hemolytic anemia (wAIHA), a disease with no FDA-approved therapies

IMAAVY® (nipocalimab-aahu) demonstrated rapid onset and durable hemoglobin response in a pivotal Phase 2/3 study of warm autoimmune hemolytic anemia (wAIHA), a disease with no FDA-approved therapies

  • Johnson & Johnson
  • 10 Jun 2026
The Digital Pharma Advances Conference 2026

Most Popular
June   2026
M T W T F S S
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30          

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.